----item----
version: 1
id: {90C524AA-1578-4AC3-9F36-EFA19E5C9739}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/11/05/Santen switches to pure ophthalmic business
parent: {AB3D0A5F-5AD9-4FF9-983E-109114074A87}
name: Santen switches to pure ophthalmic business
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c76f3667-d787-4a96-b05f-caf9a7a8cda5

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{07CF1C44-428A-445B-98D8-5EA9905BD7C5}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{29C8E5B9-B01E-4DEE-A123-14D70756095B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 43

Santen switches to pure ophthalmic business
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 43

Santen switches to pure ophthalmic business
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1719

<p>Japanese firm Santen Pharmaceutical is reorganizing its business to have a sole focus on ophthalmology. </p><p>Santen is aiming to become one of the top three ophthalmic pharmaceutical companies in the world by 2020. As a result it has assigned its anti-rheumatic pharmaceuticals to Hyperion Pharma under a simplified company-split method, made possible under the Company Act of Japan. </p><p>In succession to this action, Showa Yakuhin, a pharmaceutical company being advised by Unison Capital, intends to merge its pharma business with the anti-rheumatic pharmaceuticals being taken on by Hyperion (also a Unison Capital company). </p><p>Analysts at Jefferies said they viewed Santen's transition "positively." They highlighted recent examples of "major progress" in the company's ophthalmic pipeline: DE-109, which is in development for the treatment of uveitis, was filed for approval in Europe in February this year; DE-111 for glaucoma was filed in Asia in March; a Phase IIb study of DE-117, an EP2 agonist for glaucoma, has been completed in the US; and finally Ikervis (ciclosporin), was <a href="http://www.scripintelligence.com/researchdevelopment/CHMP-OK-for-Santens-Ikervis-in-severe-keratitis-356339" target="_new">approved in Europe</a> in March this year for the treatment of severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes.</p><p>The scheduled date for the absorption-type company split is 3 August 2015. After the transition Hyperion will be responsible for the manufacturing and sales activities of the anti-rheumatic products currently held by Santen. Meanwhile, Santen will receive JPY45bn ($375m) in cash from Hyperion. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 111

<p>Japanese firm Santen Pharmaceutical is reorganizing its business to have a sole focus on ophthalmology. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 43

Santen switches to pure ophthalmic business
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151105T130713
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151105T130713
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151105T130713
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028693
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 43

Santen switches to pure ophthalmic business
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358289
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042344Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c76f3667-d787-4a96-b05f-caf9a7a8cda5
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042344Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
